Predictive proteomic signatures from baseline blood that identify responders before treatment — analysis-only, your data stays in-house.

Many therapies work — but only in a subset of patients. ibiomic identifies that subset before treatment.

We analyze baseline blood proteomics from your existing cohort and derive compact, interpretable signatures that predict who will respond — so you can enrich enrollment, strengthen the label, and explain non-responders.

We are analysis-only: your samples and data stay in-house. We deliver the signature, the out-of-sample validation, and the biology — you keep ownership.

Our method is indication-agnostic; recent focus areas include immuno-inflammatory disease and oncology.

• You share de-identified baseline proteomics (Olink / SomaScan) + response outcomes from a completed or ongoing cohort. Your samples and data stay in-house.

• We discover minimal, interpretable signatures that separate responders from non-responders — cross-validated out-of-sample, returned as several equivalent panels, each with its biological rationale.

• You confirm on a deployable assay. Your lab or CRO measures the selected proteins with a targeted clinical assay (e.g. ELISA / MS); we re-fit the formula to that platform — so the result is not Olink-only, but deployable.

• You get a responder score — a single interpretable index, ready for trial enrichment, companion-diagnostic strategy, or standard assays.

• Robust — stable across cohorts and measurement platforms.

• Low-dimensional — a handful of proteins, not hundreds.

• Interpretable — grounded in biological system behavior, not black-box models.

• Redundant by design — we return several equivalent minimal panels, so you have a fallback if a protein or assay is unavailable. Penalized regression (LASSO / elastic net) gives you one fragile signature; we give you options.

• Deployable — we bridge discovery to a targeted clinical assay and re-fit the formula, so you are not left with a research-only Olink signature.

Translational medicine, biomarker, and clinical development teams in pharma and biotech. Our method is indication-agnostic — we work wherever baseline blood proteomics and response data exist. Recent focus areas include immuno-inflammatory disease and oncology.

The first step is a no-cost feasibility call: we review your trial and response data and scope a focused, paid pilot to find responder vs non-responder signatures in your data. The validated signatures, minimal panels, and biological interpretation are delivered in the pilot.

contacts@ibiomic.com

Interested in collaboration, early access, or learning more about ibiomic?

You can email us directly, or submit a request via this form.